Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Interim Results for Lewy Body Dementia Drug Could Pave the Way for Phase III Clinical Trial

XTALKS VITALS NEWS

Dementia

So far, 11 patients have been treated with nelotanserin, and patients showed statistically significant improvements in extrapyramidal signs – such as tremor – compared to the placebo.

Share this!

February 14, 2017 | by Sarah Hand, M.Sc.

Axovant Sciences has released positive interim results from its Phase II clinical trial for the company’s investigational Lewy body dementia drug, nelotanserin. So far, 11 patients have been treated with nelotanserin, and patients showed statistically significant improvements in extrapyramidal signs – such as tremor – compared to the placebo.

According to Axovant, these promising results have prompted the biopharma company to begin planning for a Phase III clinical trial. The company plans to start recruiting patients for this late-stage trial in the second half of 2017.

Nelotanserin is a selective inverse agonist of the 5HT2A receptor – a protein implicated in the motor symptoms and visual hallucinations experienced by individuals with Lewy body dementia. As such, the drug is being developed to address these neuropsychiatric disturbances and sleep problems common in patients with dementia.

The primary outcome of this trial was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II + III. The Phase II study was also focused on assessing the safety of nelotanserin, with the study investigators writing that no serious drug-related adverse events were reported.



“I am intrigued by the benefits observed on the UPDRS in this study,” said Dr. James Leverenz, Chair, Scientific Advisory Council of the Lewy Body Dementia Association and Director of the Cleveland Lou Ruvo Center for Brain Health at the Cleveland Clinic. “If a single drug could simultaneously address the motor and neuropsychiatric symptoms of Lewy body dementia, which the published literature suggests may be the case for 5HT2A antagonists, it would represent a unique and important advance for the treatment of this condition. I look forward to reviewing the full dataset later this year.”

As Lewy body dementia is the second most common form of the disease next to Alzheimer’s, Axovant believes that there is a need for more therapeutics which address the Parkinsonism symptoms patients face. While full data for the Phase II trial is expected to be released in mid-2017, the company is already considering the trial a success as only half the target number of patients were enrolled in the study.

“We are pleased with the preliminary results of this small pilot study which supports our belief that nelotanserin could be a promising investigational drug candidate for patients suffering from Lewy body dementia,” said Dr. Lawrence Friedhoff, Chief Development Officer of Axovant Sciences. “We plan to discuss with FDA and other regulators the parameters of a potential Phase III registration program while we await results from the full cohort of patients in this study. We will carefully examine whether the UPDRS treatment benefit observed in this interim analysis will be maintained in the final analysis when the remaining patients complete this study.”


Keywords: Dementia, Clinical Trial, Interim Results


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.